Lunsumio is a CD20xCD3 T-cell engaging bispecific antibody. Lunsumio is approved in the EU for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.
Lunsumio is a first-in-class fixed-duration CD20xCD3 T-cell engaging bispecific antibody. Lunsumio is approved in more than 50 countries, including the EU and the US, for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions.